Experimental CAR-T therapy targets tough lymphoma
NCT ID NCT06248086
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 29 times
Summary
This early-phase study tested a new treatment called ASP2802 for adults with CD20-positive B-cell lymphoma that returned or stopped responding to prior therapy. The treatment involves collecting a patient's own immune cells, modifying them to better fight cancer, and giving them back along with a booster protein (MA-20). The main goals were to check safety and find the right dose. The study was terminated early after enrolling only one person.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site AU61004
Sydney, 3065, Australia
Conditions
Explore the condition pages connected to this study.